Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 253

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 253
---
120

TABLE OF CONTENTS

(2) Assumes that no additional stockholders exercise redemption rights. (3) Assumes that an additional 50%, or 87,238, shares of Iris Class A Common Stock are redeemed for cash. (4) Number of shares determined based on a price of $10.00 per share. Such price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. Shares to be Issued on a Fully-diluted Basis

| ​                                 | ​ | ​ | AssumingNo AdditionalRedemptions(1)(2) |   |            |   | ​ | ​ | %Ownership |   |      |   | ​ | ​ | Assumingan additional50%Redemption(1)(3) |   |            |   | ​ | ​ | %Ownership |   |      |   | ​ | ​ | AssumingMaximumRedemptions(1) |   |            |   | ​ | ​ | %Ownership |   |      |   | ​ |
| Iris public stockholders          | ​ | ​ | ​                                      | ​ |    174,477 | ​ | ​ | ​ | ​          | ​ |  0.5 | ​ | ​ | ​ | ​                                        | ​ |     87,238 | ​ | ​ | ​ | ​          | ​ |  0.3 | ​ | ​ | ​ | ​                             | ​ |          0 | ​ | ​ | ​ | ​          | ​ |    0 | ​ | ​ |
| Sponsor and independent directors | ​ | ​ | ​                                      | ​ |  6,900,000 | ​ | ​ | ​ | ​          | ​ | 20.0 | ​ | ​ | ​ | ​                                        | ​ |  6,900,000 | ​ | ​ | ​ | ​          | ​ | 20.0 | ​ | ​ | ​ | ​                             | ​ |  6,900,000 | ​ | ​ | ​ | ​          | ​ | 20.1 | ​ | ​ |
| Deferred underwriting commissions | ​ | ​ | ​                                      | ​ | 700,000(4) | ​ | ​ | ​ | ​          | ​ |  2.0 | ​ | ​ | ​ | ​                                        | ​ | 700,000(4) | ​ | ​ | ​ | ​          | ​ |  2.